New drug cocktail shows promise against rare sarcomas
NCT ID NCT06128863
First seen Jan 10, 2026 · Last updated May 02, 2026 · Updated 14 times
Summary
This study tests a combination of two immunotherapy drugs (pembrolizumab and eftilagimod alpha) plus radiation before surgery for soft tissue sarcoma. The goal is to see if this treatment shrinks tumors more effectively. The trial involves 40 adults with high-risk, non-spread sarcomas and is currently active but not recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOTHERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Maria Sklodowska-Curie National Research Institute of Oncology
Warsaw, 00-738, Poland
Conditions
Explore the condition pages connected to this study.